Aleksandra Georgievski

Aleksandra Georgievski

Auto-generated profile, based on publicly available information

Aleksandra Georgievski

Center of Translational and Molecular Medicine, UMR1231, Inserm-Université de Bourgogne, Dijon, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Purpose: Cluster of differentiation 40 (CD40) is expressed on B-cell acute lymphoblastic leukemia (B-ALL) cases. However, the effect of CD40 activation on B-ALL cells has never been tested in vivo. Experimental Design: The aim of our preclinical study was to investigate the therapeutic potential of a CD40 agonist in the treatment of B-ALL using patient-derived xenograft mouse models. Results: Intravenous administration of the CD40 agonist significantly impeded B-ALL cell proliferation and growth in vivo, accompanied by rapid activation of the ERK pathway, which led to the induction of apoptosis and disruption of cell-cycle progression. Cotreatment with a specific inhibitor of ERK further demonstrated that CD40 stimulation induced the proapoptosis of B-ALL cells in an ERK-dependent manner. Proteomic analysis revealed alterations in key signaling pathways associated with B-ALL expansion and maintenance. Moreover, the CD40 agonist markedly reduced the frequency of leukemia-initiating cells and leukemia development in patient-derived xenograft mice. Our study showed that the CD40 agonist can be associated with chemotherapeutic agents such as vincristine and dexamethasone, and this combination showed improved effectiveness. Additionally, the CD40 agonist was more effective on pre–B-ALL (EGIL B-III) that expressed CD40 than on common B-ALL (EGIL B-II) that lacked CD40 expression. Conclusions: These findings suggest that CD40 agonists are promising immunotherapeutic candidates for pediatric B-ALL, warranting further clinical investigations to improve patient outcomes in CD40-expressing B-ALL.

6 January 2025
Verified
Other
Open access
PDF file
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Supplementary Table S4. Flow cytometry analysis of specific markers expressed by B-ALL PDX cells.

6 January 2025
Verified
Other
Open access
PDF file
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Supplementary Figure S9. Combination of CD40 agonist and chemotherapy significantly reduces B-ALL development in PDX mice.

6 January 2025
Verified
Other
Open access
PDF file
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Supplementary Figure S4. Agonist CD40 binds primary B-ALL cells.

6 January 2025
Verified
Other
Open access
PDF file
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Supplementary Figure S7. Molecular markers expressed by B-ALL PDX models.

6 January 2025
Verified
Other
Open access
PDF file
Pierre-Simon BellayePierre-Simon Bellaye
Pierre-Simon Bellaye
AGAleksandra Georgievski
Aleksandra Georgievski
PBPaola Ballerini
Paola Ballerini
BBBoutheina Bouslama
Boutheina Bouslama
CRCorentin Richard
Corentin Richard
RQRonan Quéré
Ronan Quéré
Supplementary Table S6. List of primers used for qPCR on AP-1 target genes.